Biotech industry leaders in Georgia, ground zero for the voting rights controversy, expressed solidarity with the ideas expressed in a letter signed by biotech leaders supporting voting rights, but opposed their calls to consider shunning...

Immune medicines company Repertoire Immune Medicines Inc. raised $189 million in a series B financing from founding investor Flagship Pioneering and other investors including Softbank Vision Fund 2i, the Public Sector Pension Investment Board (PSP...

Affimed has been working on NK cell engagers since before T cell engagers became popular but the latest data — which catapulted Affimed over the $1 billion market cap threshold — suggest the approach is...

Scholar Rock is moving apitegromab (SRK-015) into Phase III this year, but the myostatin blocker is proving to have a more durable effect in some spinal muscular atrophy patient cohorts than others. The company’s stock...

SomaLogic Inc. is merging with CM Life Sciences II, a SPAC sponsored by Casdin Capital and Corvex Management (NASDAQ:CMIIU). The deal is expected to give the proteomics company up to $651 million in cash, including $375...

Less than three months after revealing its series A round, preclinical start-up Biomea Fusion has filed for a NASDAQ listing to fund development of its first irreversible small-molecule cancer therapy, a menin inhibitor that the company...

Asher Bio emerged from stealth Tuesday with a $55 million series A led by Third Rock and a platform to improve the safety and efficacy of cytokine therapies for cancer.  Boxer Capital, Invus and seed...

An $80 million crossover series E round will support 12-year-old Aura’s first pivotal trial based on its virus-like particle conjugation technology: a Phase III study in choroidal melanoma, an ocular cancer.  CEO Elisabet de los...

Insitro Inc. said existing investor Canada Pension Plan Investment Board led its new $400 million series C round, which builds on a $143 million series B closed in May 2020. Also backing the machine learning-guided drug...

Crossover investors have poured into Graphite’s $150 million series B round six months after the gene therapy company’s launch based on technology out of the Stanford lab of Matthew Porteus, setting it on a quick path...